Sanofi, Regeneron nab EU approval for PCSK9 med; Endo wraps Par buyout; Allergan, Mylan launch generic Invega;

@FiercePharma: AKC-funded study IDs similar lymphoma gene types in dogs and people. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun Pharma unit Mutual Pharma recalls 216,766 bottles that may have chemical leaching labels. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Roche is 'well placed' for U.S. pricing tussle, CEO says. Report | Follow @CarlyHFierce

> Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 med, Praluent, has won approval in the EU; its head-to-head rival from Amgen ($AMGN), Repatha, got a similar approval this summer. Release

> Endo ($ENDP) wrapped up its deal for Par Pharmaceutical and updated its financial projections for the year; it now expects up to $3.27 billion in 2015 revenue. Release

> Allergan ($AGN) and Mylan ($MYL) launched their generic versions of Johnson & Johnson's ($JNJ) antipsychotic drug Invega. Release | Release

> The FDA approved Bayer's Betaconnect, an electronic autoinjector that delivers its older multiple sclerosis med Betaseron. Report

> Japan has green-lighted Teva's ($TEVA) MS med Copaxone. Release

Medical Device News

@FierceMedDev: ICYMI: In latest biopharma-med tech pairing, Teva snaps up respiratory compliance tracker Gecko. More | Follow @FierceMedDev

@StacyALawrence: JDRF, ADA redefine Type 1 diabetes framework to encourage early diagnosis, prevention. Story | Follow @StacyALawrence

@VarunSaxena2: From @FierceMedDev's special report on recalls: Patients struggle to safely use HeartWare's blood pump. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Shire chalks up victory in Vyvanse patent battle. Article | Follow @EmilyWFierce

> Medtronic to buy stent retriever cover startup Lazarus Effect for $100M. Report

> Intestinal resurfacing procedure to treat diabetes shows promise in early stage trial. Article

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novo scores a game-changing diabetes approval, reversing an embarrassing rejection. Article | Follow @JohnCFierce

@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce

> Roche scores an MS first with a potential blockbuster on its hands. Story

> Roche wins kudos for game-changing atezolizumab cancer data. More

> Westphal's Verastem concedes lead drug flopped in PhII mesothelioma study. Article

Animal Health News

> USDA unveils plan to battle avian flu if it re-emerges this fall. Story

> Sanofi rumored to be weighing Merial spinoff. Report

> Investors trounce Aratana on dashed hopes for canine lymphoma drugs. More

> AKC-funded study IDs similar lymphoma gene types in dogs and people. Story

> Rhizen moves into midstage trial of pill to treat canine lymphoma. Article

Biotech IT News

> BioClinica buys pharmacovigilance outfit to continue evolution. Article

> AstraZeneca opens data vault for cancer combo efficacy prediction challenge. Report

> Feds prioritize researcher access to health data in IT action plan. More

> Bayer pairs Genedata Profiler and iRODS to manage omics data analysis. Story

> Venter's HLI strikes low-cost exome sequencing deal to swell data repository. Article

Pharma Marketing News

> International payer report shows U.S. prices almost 10X higher for some meds. Item

> Novartis backs DC Comics graphic novel starring rare-disease hero and his canine sidekick. More

> NEJM: FDA's proposed risk-disclosure guidelines still aren't enough. Story

> Don't be quick to peg Merck's Keytruda in second place for NSCLC, analyst says. Article

> Not so fast, Hillary. Ad industry will fight with pharma against DTC tax moves. More

And Finally... Over the long term, diet and exercise are better than medication at preventing diabetes. Report